Tumors of the male urogenital system are frequent (with an incidence in the United States of 25%). They usually have a long latency period and a high percentage of posttherapy survival. Patients affected by malignant urogenital lesions therefore require a long period of monitoring to identify recurrence of disease requiring adjuvant or salvage treatment as early as possible. The task of the urologist is to identify a strategy which on the one hand guarantees patient safety and on the other maintains costs within acceptable levels. This is prompted by the fact that apart from clinical and laboratory findings, patient follow-up principally consists of radiologic examinations. © 2009 Springer-Verlag Milan.
Clinical approach
Cunico S. C.;Moroni A.;Mirabella G.;Simeone C.;Olivetti L.
2009-01-01
Abstract
Tumors of the male urogenital system are frequent (with an incidence in the United States of 25%). They usually have a long latency period and a high percentage of posttherapy survival. Patients affected by malignant urogenital lesions therefore require a long period of monitoring to identify recurrence of disease requiring adjuvant or salvage treatment as early as possible. The task of the urologist is to identify a strategy which on the one hand guarantees patient safety and on the other maintains costs within acceptable levels. This is prompted by the fact that apart from clinical and laboratory findings, patient follow-up principally consists of radiologic examinations. © 2009 Springer-Verlag Milan.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
